2026年11月4日星期三
M
Weltübersicht
Globale Kurznachrichten
NTT to help Japanese companies update at-risk aging IT with AI— 日经 Nikkei Asia5 things to know about the US midterms and what they mean for Asia— 日经 Nikkei AsiaChina's cable-cutting threat reaches Taiwan and the Philippines— 日经 Nikkei AsiaVienna entrepreneur takes leaders on lux train to China to foster ties— 日经 Nikkei AsiaBangladesh garment factories become second schools for women— 日经 Nikkei AsiaThailand to raise tax on imported EVs to 35% as Chinese brands gain ground— 日经 Nikkei AsiaWhy PC makers are turning back to China— 日经 Nikkei AsiaIndonesia chief of staff sacked for allegedly wiretapping President Prabowo— 日经 Nikkei AsiaNTT to help Japanese companies update at-risk aging IT with AI— 日经 Nikkei Asia5 things to know about the US midterms and what they mean for Asia— 日经 Nikkei AsiaChina's cable-cutting threat reaches Taiwan and the Philippines— 日经 Nikkei AsiaVienna entrepreneur takes leaders on lux train to China to foster ties— 日经 Nikkei AsiaBangladesh garment factories become second schools for women— 日经 Nikkei AsiaThailand to raise tax on imported EVs to 35% as Chinese brands gain ground— 日经 Nikkei AsiaWhy PC makers are turning back to China— 日经 Nikkei AsiaIndonesia chief of staff sacked for allegedly wiretapping President Prabowo— 日经 Nikkei Asia

[Articles] Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial

Quelle 柳叶刀 LancetVor 11 Tagen
Inhaltszusammenfassung

Mitapivat, an oral pyruvate kinase activator, with a novel mechanism that ameliorates haemolytic anaemia, has the potential to be an effective and convenient d…

Diese Website bietet nur Titel- und Zusammenfassungsindexe. Der vollständige Inhalt und das Urheberrecht liegen beim ursprünglichen Herausgeber. Bitte klicken Sie auf den Original-Link, um ihn zu lesen.

Zum Originaltext
Zugehöriger Kanal
Gesundheit
Zugehörige Region
Vereinigtes Königreich
Originalsprache
English
Eintragsnummer
health-94d31632

Comments 0 comments

No comments yet. Be the first.

[Articles] Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial · Weltübersicht